Trump Overhauls Section 232 Tariffs on Patented Pharmaceutical Products
Summary
President Trump issued a Section 232 proclamation imposing tariffs up to 100% on patented pharmaceutical products and ingredients. Generic drugs, biosimilars, and specialty pharmaceuticals including orphan drugs and cell therapies are excluded. Companies with approved onshoring plans receive reduced rates of 20% until 2030, while those with pharmaceutical pricing agreements pay 0% until January 2029.
What changed
The April 2026 proclamation establishes Section 232 tariffs on patented pharmaceuticals at a default rate of 100%, marking a significant escalation in trade enforcement targeting the pharmaceutical industry. Implementation occurs in phases: companies listed in Annex III face tariffs starting July 31, 2026, with all other covered companies subject to tariffs from September 29, 2026.
Importers of patented drugs must immediately evaluate their exposure and pursue available relief mechanisms. Companies may reduce or eliminate tariffs through approved onshoring plans (20% rate), pharmaceutical pricing agreements (0% rate), or drug designation requests to Commerce. Generic and biosimilar manufacturers are unaffected, creating potential competitive advantages for non-patented alternatives.
What to do next
- Assess tariff exposure for imported patented pharmaceutical products
- Evaluate eligibility for relief mechanisms (onshoring plans, pricing agreements, drug exclusions)
- Monitor for Commerce Department criteria on duty mitigation programs
Penalties
100% tariff rate on covered patented pharmaceuticals and ingredients; 20% for companies with approved onshoring plans; 15% for EU/Japan/Switzerland/Liechtenstein; 10% for UK
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
April 10, 2026
Trump Overhauls Section 232 Tariffs on Patented Pharmaceutical Products
Ngosong Fonkem Amundsen Davis LLC + Follow Contact LinkedIn Facebook X Send Embed On April 2, 2026, President Trump issued a proclamation under section 232 tariff authority imposing sweeping new tariffs on patented pharmaceutical products and ingredients imported into the U.S., with rates reaching up to 100 percent and taking effect as early as July 2026 for certain companies.
The implementation timelines and rates vary depending on the importing company’s size, product country of origin, and trade deals with partners. Companies identified in Annex III will face tariffs beginning July 31, 2026, while all other covered companies will become subject to the tariffs on September 29, 2026.
The proclamation is implemented through Annexes I–IV, which define covered products, exclusions, company‑specific treatment, and available relief mechanisms, and are summarized below.
Tariff Rates for Covered Products
The default tariff rate on patented pharmaceuticals and ingredients shall be 100 percent. However, exceptions to this include:
- Products of companies that have “onshoring plans” approved by the secretary of commerce shall be assessed a tariff rate of a 20 percent, which shall increase to 100 percent on April 2, 2030.
- Companies that have entered into pharmaceutical pricing agreements shall be assessed a tariff rate of zero percent until January 20, 2029 per the terms of the agreements.
- Products from some countries that have recently negotiated trade deals with the U.S., including the European Union, Japan, Switzerland, and Liechtenstein, shall be assessed a tariff rate of 15 percent, while the UK is assessed a tariff rate of 10 percent.
Products Excluded From Section 232 Tariffs on Pharmaceuticals
Generic and biosimilar pharmaceuticals, as defined in Annex I, shall not be subjected to the 232 tariffs. “Specialty pharmaceutical products” are also exempt. This includes:
- Orphan drugs;
- Nuclear medicines;
- Plasma derived therapies;
- Fertility treatments;
- Cell and gene therapies;
- Antibody drug conjugates;
- Medical countermeasures; and
- Others identified by the secretary of commerce, as well as products for animal health if they are from trade deal countries or meet an urgent U.S. health need.
What Does This New Tariff Mean for Importers of Patented Pharmaceuticals?
Importers of patented pharmaceutical products should begin assessing their exposure immediately and consider whether they qualify for available relief mechanisms . The proclamation establishes several mechanisms by which companies can reduce or eliminate their tariff exposure. For example, the Commerce Department and the Department of Health and Human Services shall establish the criteria for companies to enter into “onshoring plans” and pharmaceutical pricing agreements. The Commerce Department may also designate drugs for exclusion from the tariffs. These undoubtedly provide importers with several avenues to mitigate or reduce their tariffs exposure.
Should importer have questions regarding these duty mitigation steps reach out to us. In the meantime, we will continue to keep you updated should new developments become available.
Related Posts
- Trump Overhauls Section 232 Tariffs on Steel, Aluminum, and Copper
- Trump Tariffs: CBP Proposes Refund Process Following Court of International Trade Order
- Requesting Trump Tariff Refunds Through Protest Filings
Latest Posts
- Trump Overhauls Section 232 Tariffs on Patented Pharmaceutical Products
- Accessing New Markets While Managing Business Risks See more »
DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.
©
Amundsen Davis LLC
Written by:
Amundsen Davis LLC Contact + Follow Ngosong Fonkem + Follow more less
PUBLISH YOUR CONTENT ON JD SUPRA
- ✔ Increased readership
- ✔ Actionable analytics
- ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra
Published In:
Department of Health and Human Services (HHS) + Follow Drug Pricing + Follow Imports + Follow International Trade + Follow Pharmaceutical Industry + Follow Pharmaceutical Patents + Follow Presidential Proclamations + Follow Section 232 + Follow Tariffs + Follow Trump Administration + Follow U.S. Commerce Department + Follow US Trade Policies + Follow Antitrust & Trade Regulation + Follow Health + Follow International Trade + Follow more less
Amundsen Davis LLC on:
"My best business intelligence, in one easy email…"
Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Sign Up Log in ** By using the service, you signify your acceptance of JD Supra's Privacy Policy.* - hide - hide
Named provisions
Related changes
Get daily alerts for JD Supra Trade Law
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from Amundsen Davis.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when JD Supra Trade Law publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.